FDA application holder
Strides Pharma International Ag
The Orange Book identifies this organization as the applicant responsible for ANDA 088946.
Orange Book drug · Generic (ANDA)
Hydra-zide
Hydralazine Hydrochloride; Hydrochlorothiazide
DiscontinuedANDA 088946 Strides Pharma Intl
Approved
Oct 21, 1985
Strengths
1
Listed patents
0
Applications
3
What does the FDA Orange Book show for Hydra-zide?
Hydra-zide contains Hydralazine Hydrochloride; Hydrochlorothiazide and appears in 3 FDA Orange Book applications. ANDA 088946 is the lead filing, with 1 presentation shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.
- FDA applications
- 3; lead ANDA 088946
- Lead application holder
- Strides Pharma International Ag
- Product presentations
- 1
- Marketing categories
- Discontinued
- Reference roles
- None posted
- TE codes
- None posted
- Listed patents
- 0
- Exclusivity records
- 0
Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.
The listed applicant holds the FDA application; this field does not establish the product manufacturer.
Each FDA product number remains tied to its own strength, dosage form, route, and status.
Orange Book marketing categories do not establish real-time inventory or commercial availability.
RLD and RS designations are presentation-specific, not inferred from the trade name.
Therapeutic-equivalence codes apply only within the matching Orange Book product heading.
A zero means none appear in this snapshot, not that no patent rights exist.
FDA exclusivity and listed patent protection are distinct regulatory concepts.
Sourced from the official FDA Orange Book data file · snapshot refreshed
FDA product-presentation matrix
Every product number in this exact application
| Product | Strength | Dosage form / route | Marketing status | TE code | Reference role |
|---|---|---|---|---|---|
| 001 | 50MG;50MG | CAPSULEORAL | Discontinued | None posted | None posted |
Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.
Who is responsible for this application?
Application holder is not the same as manufacturer
Manufacturer status
Not established by the Orange Book
A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.
Regulatory interpretation
What the record means, and what it does not
FDA marketing status
1 presentation listed as on the Discontinued Drug Product List
A discontinued-list entry does not, by itself, show why marketing stopped or whether FDA determined the product was withdrawn for safety or effectiveness.
Therapeutic equivalence
No TE code is posted for this application
No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.
Patent & exclusivity record
No listed patents or exclusivity records
This means none appear for this application in the current Orange Book files. It is not a freedom-to-operate opinion and does not rule out unlisted patents, regulatory barriers, or product-specific rights.
Same-ingredient landscape
16 other ANDAs and 1 other NDA found
0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.
Which products are meaningfully comparable?
Exact ingredient + dosage form + route cohorts
ANDA 088946 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.
Capsule · Oral
Hydralazine Hydrochloride; Hydrochlorothiazide
- Product rows
- 17
- Active applications
- 0
- Active with AB row
- 0
Hydralazine Hydrochloride And Hydrochlorothiazide · ANDA 089200Hydralazine Hydrochloride And Hydrochlorothiazide · ANDA 089201Hydralazine Hydrochloride W/ Hydrochlorothiazide 100/50 · ANDA 088358Hydralazine Hydrochloride W/ Hydrochlorothiazide 25/25 · ANDA 088356Hydralazine Hydrochloride W/ Hydrochlorothiazide 50/50 · ANDA 088357Hydralazine Hydrochloride And Hydrochlorothiazide · ANDA 085457
Why are clinical sections unavailable?
Exact application-label matching status
Exact source match queuedQueue ANDA-088946
No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.
Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.
Product detail
ANDA 088946
Discontinued
- Strength
- 50MG;50MG
- Dosage form
- CAPSULE
- Route
- ORAL
- Marketing status
- Discontinued
Key dates
Approval, patents, exclusivityApproval
FDA approval date of this drug product.
41 yr 4 mo ago
Today
Pharmaceutical detail
FDA product recordActive ingredient
HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
Strength
50MG;50MG
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
ANDA 088946
Product number
001
Marketing status
Discontinued
Reference listed drug (RLD)
No
Reference standard (RS)
No
Listed patents
Orange Book patent fileNo patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Other FDA applications for Hydra-zide
2 additional filings · 2 generic
The FDA has approved 3 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.
| Application | Applicant | Approved | Strengths | TE code | Status |
|---|---|---|---|---|---|
| ANDA 088957 | Strides Pharma Intl | Oct 21, 1985 | 1 | — | Discontinued |
| ANDA 088961 | Strides Pharma Intl | Oct 21, 1985 | 1 | — | Discontinued |
Active-ingredient family
Brand + generics
Generic (ANDA) of Hydralazine Hydrochloride; Hydrochlorothiazide
- —Apresoline-esidrixBrand (NDA)
NDA 012026 · Novartis
- 1987Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 089200 · Superpharm
- 1987Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 089201 · Superpharm
- 1984Hydralazine Hydrochloride W/ Hydrochlorothiazide 100/50Generic (ANDA)
ANDA 088358 · Ivax Pharms
- 1984Hydralazine Hydrochloride W/ Hydrochlorothiazide 25/25Generic (ANDA)
ANDA 088356 · Ivax Pharms
- 1984Hydralazine Hydrochloride W/ Hydrochlorothiazide 50/50Generic (ANDA)
ANDA 088357 · Ivax Pharms
- 1982Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 085457 · Watson Labs
- 1982Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 085446 · Watson Labs
- 1982Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 085440 · Watson Labs
- 1982Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 087608 · Solvay
- 1982Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 087213 · Solvay
- 1982Hydralazine Hydrochloride And HydrochlorothiazideGeneric (ANDA)
ANDA 087609 · Solvay
How to use this record responsibly
Scope, limitations, and primary sources
What to verify before making a decision
- The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
- RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
- Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
- Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
- The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.
Official FDA references
- Electronic Orange Book record
- Orange Book preface and TE-code policy
- FDA product, patent, and exclusivity data files
Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.
Hydra-zide: frequently asked questions
Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.
Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of ANDA 088946 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
